Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CD19 CAR-T Cell Therapy
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Galapagos
Deal Size : $14.0 million
Deal Type : Acquisition
Galapagos to Acquire CellPoint And AboundBio to Accelerate Access to Next-Generation Cell Therapies
Details : The aim is to leverage CellPoint’s platform for novel CAR-Ts originating from AboundBio’s unique fully human antibody-based library and biological drug discovery and engineering capabilities, with the goal of bringing three next-generation CAR-T cand...
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 21, 2022
Lead Product(s) : CD19 CAR-T Cell Therapy
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Galapagos
Deal Size : $14.0 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?